Boston Scientific Estimate Lowered and 4 Stock Analyses Not to Ignore
Cepheid (NASDAQ:CPHD): Goldman stated that shares of Cepheid continue to be oversold after the analyst meeting and also stated that management failed to reveal any new incremental information. The firm still thinks that Cepheid be the head of the MDx market, and it recommends buying shares on weakness.
Genomic Health Inc. (NASDAQ:GHDX): JPMorgan has stated that NanoString announced its Pam50 breast is able to be CE marked, allowing commercialization outside of the U.S. According to the firm, this is an incremental negative for Genomic Health’s OncotyeDX breast cancer franchise that has 95 percent market share.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
United Continental Holdings (NYSE:UAL): According to Imperial Capital, investors should use weakness in the company’s shares to accumulate positions in the stock. The firm views the company’s long-term fundamentals as remaining intact after its Q3 guidance, and it keeps its Outperform rating on the stock.
Boston Scientific Corporation (NYSE:BSX) FY12 EPS estimate has been reduced by Argus to 43c-45c from 48c-50c, due to the company’s ongoing trend of losing market share in drug-eluting stents and defibrillators. Argus believes that the company has been losing share to Medtronic (NYSE:MDT) in both categories, and it keeps a Hold rating on the stock
Urban Outfitters Inc. (NASDAQ:URBN) analyst day, today, is believed by Morgan Stanley to have the potential to increase investor confidence in management and its turnaround strategy. The company’s analyst meeting started at 1:00 EST time, and the firm gives the shares an Overweight rating.
Don’t Miss: Will Google Kill Siri?